← All trials
NCT06044467
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2018
- Primary completion
- Apr 27, 2020
- Completion date
- Apr 27, 2020
- First posted
- Sep 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 16
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ChemomAb Ltd.Lead sponsor
- Hebrew UniversityOverall official - principal investigator
- ChemomAb Ltd.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.